Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
Manuel Tsiang, James F. Rooney, John J. Toole, Craig S. Gibbs – 30 December 2003 – In a recent phase II clinical study, 13 chronic hepatitis B–infected patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4.1‐log10 decrease in plasma hepatitis B virus (HBV)‐DNA levels. The decline of viral load during therapy displayed a biphasic kinetic profile that was modeled to determine the efficacy of inhibition of viral production, as well as kinetic constants for the clearance of free virus and the loss of infected cells.